Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does DEFIBROTIDE Cause Interstitial lung disease? 63 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 63 reports of Interstitial lung disease have been filed in association with DEFIBROTIDE (DEFITELIO). This represents 1.7% of all adverse event reports for DEFIBROTIDE.

63
Reports of Interstitial lung disease with DEFIBROTIDE
1.7%
of all DEFIBROTIDE reports
45
Deaths
56
Hospitalizations

How Dangerous Is Interstitial lung disease From DEFIBROTIDE?

Of the 63 reports, 45 (71.4%) resulted in death, 56 (88.9%) required hospitalization, and 4 (6.3%) were considered life-threatening.

Is Interstitial lung disease Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for DEFIBROTIDE. However, 63 reports have been filed with the FAERS database.

What Other Side Effects Does DEFIBROTIDE Cause?

Off label use (1,323) Venoocclusive disease (576) Death (463) Multiple organ dysfunction syndrome (372) Venoocclusive liver disease (355) Intentional product use issue (201) Hypotension (169) Haemorrhage (156) Sepsis (143) Acute graft versus host disease (140)

What Other Drugs Cause Interstitial lung disease?

METHOTREXATE (3,049) RITUXIMAB (2,458) PEMBROLIZUMAB (2,113) PREDNISONE (1,850) CYCLOPHOSPHAMIDE (1,725) NIVOLUMAB (1,538) AMIODARONE (1,421) DOXORUBICIN (1,352) ETANERCEPT (1,267) ADALIMUMAB (1,250)

Which DEFIBROTIDE Alternatives Have Lower Interstitial lung disease Risk?

DEFIBROTIDE vs DEFLAZACORT DEFIBROTIDE vs DEGARELIX DEFIBROTIDE vs DELAFLOXACIN MEGLUMINE DEFIBROTIDE vs DELAMANID DEFIBROTIDE vs DELANDISTROGENE MOXEPARVOVEC-ROKL

Related Pages

DEFIBROTIDE Full Profile All Interstitial lung disease Reports All Drugs Causing Interstitial lung disease DEFIBROTIDE Demographics